Related references
Note: Only part of the references are listed.Complex patterns of ETS gene alteration arise during cancer development in the human prostate
J. Clark et al.
ONCOGENE (2008)
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
G. Attard et al.
ONCOGENE (2008)
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Scott A. Tomlins et al.
NATURE (2007)
A validated liquid chromatographic-tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma
Vanessa Martins et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2006)
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
DP Petrylak et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer
SA Tomlins et al.
CANCER RESEARCH (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer
G Attard et al.
BJU INTERNATIONAL (2005)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
MA Titus et al.
CLINICAL CANCER RESEARCH (2005)
Cancer incidence and mortality in Europe, 2004
P Boyle et al.
ANNALS OF ONCOLOGY (2005)
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583)
EJ Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
J Holzbeierlein et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Overview of dehydroepiandrosterone biosynthesis
RJ Auchus
SEMINARS IN REPRODUCTIVE MEDICINE (2004)
Androgen receptor mutations in androgen-in dependent prostate cancer: Cancer and Leukemia Group B Study 9663
ME Taplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The current state of hormonal therapy for prostate cancer
BA Hellerstedt et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2002)
Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone
M Morioka et al.
UROLOGIA INTERNATIONALIS (2002)
The genetics, pathophysiology, and management of human deficiencies of P450c17
RJ Auchus
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2001)
Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor
DN Grigoryev et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2000)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)